The conversation is about finding a trustworthy and affordable source for RU58841 in Europe, with a comparison between Anagenic and Actifolic. The user seeks experiences from others in the EU to avoid receiving water instead of the product.
Kintor KX-826, a hair loss treatment, is being discussed for its pricing and effectiveness, with a focus on whether the 0.9% concentration is more effective than the 0.5%. Users are seeking cheaper purchasing options.
The conversation is about a user's hair growth progress after 9 months of using oral minoxidil and finasteride, along with dermastamping. The user reports improved hair health and color, with some visible scalp remaining, and no side effects from the treatment.
A 28 year old man's 18-month journey to treat his hair loss with Dutasteride, RU58841, Minoxidil, Microneedling, Nizoral and T/GEL. He experienced some side effects along the way, including translucent semen and scalp less oily.
KY19382, a promising compound for hair loss, is not widely discussed or used. One user is currently testing it and plans to share results in a few weeks.
KX-826 combined with minoxidil significantly increases hair growth compared to minoxidil alone for treating male androgenetic alopecia, with no unexpected safety concerns. Users discuss various hair loss treatments, including KX-826, minoxidil, finasteride, and RU58841, sharing personal experiences and sourcing information.
A user discusses the legitimacy of Kintor's KX-826 for hair loss, available on Amazon through Koshine Biomedica. They decided to order it after finding a document linking Kintor and Koshine as collaborators.
An 18-year-old is seeking advice on hairstyles to manage and conceal thinning, fine hair. They are looking for a style that boosts confidence and addresses their long-standing insecurity.
A user named "EgyptStar81" who has been dealing with hair loss since age 15 due to genetics, chemotherapy and finasteride/minoxidil treatment. Possible solutions such as dutasteride, oral minoxidil, hair transplants and extensions were suggested.
A 26-year-old has seen hair improvement after 18 months on finasteride, with no side effects, and is considering switching to dutasteride despite difficulty obtaining a prescription. They also use dermastamping and are hesitant to try minoxidil, preferring to explore dutasteride first.
Users discuss aggressive promotion of Koshine 826, suspecting Kintor employees are behind it. Concerns are raised about its effectiveness, with some preferring alternatives like finasteride and minoxidil.
KX-826 may cause increased hair loss for some users, leading to concerns about its effects. One user reported no issues but also no hair regrowth, only maintenance.
A user shared their positive experience with a no shave FUE hair transplant by Dr. Ko in Seoul, including aftercare with oxygen therapy, red light therapy, and prescribed dutasteride and oral minoxidil (2.5mg daily). The procedure cost over $5,000 USD, and the user is satisfied with the results.
The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.
A user shared their 16-month hair regrowth progress using oral and topical minoxidil, dutasteride, derma rolling, and occasional keto shampoo. The conversation includes positive reactions and jokes about their impressive results.
The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.
The conversation discusses a 24-year-old Korean man's progress with hair loss treatments over 8-9 months, with specific treatments not mentioned due to redacted information. Users are commenting on the effectiveness and inquiring if Asians have better results with hair loss treatments.
The conversation is about the timeline for Kintor's phase 3 trials for GT20029 and the potential release of the product in three years. It also mentions treatments like Minoxidil, finasteride, and RU58841.
GHK-RU58841 is used for hair loss, with positive results when combined with finasteride, stemoxydine, redensyl, and alfatradiol. Users report effectiveness after adding finasteride.
The user reported maintaining hair with finasteride, minoxidil, microneedling, Nizoral, vitamins, and lifestyle changes over 18 months, and switched to topical finasteride due to side effects from the oral form. They also improved their microneedling technique.
An 18-year-old male has been taking oral finasteride 0.25 mg daily for almost four months to address hairline recession, experiencing mild sexual side effects like softer erections and lower libido. He also uses Tugain 5%, ketoconazole, and vitamins, noticing slowed shedding but no major regrowth, and seeks advice on managing side effects and hair loss.
The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.
A user shared their successful hair transplant experience with 2500 grafts by Dr. Ko in Korea, costing $8.7K, and mentioned using dutasteride and minoxidil post-surgery without side effects. The results were praised for looking natural, though some users questioned the graft count and photo authenticity.
The user is exploring KX-826 as a potential hair loss treatment due to intolerance to FDA-approved drugs like Minoxidil and finasteride. They seek fundamental help and information about KX-826.
A 17-year-old shared progress pictures after using RU58841 and Minoxidil for 2 months, showing significant hair regrowth. Another user commented on the impressive results achieved in a short time.
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.
The conversation discusses skepticism about the effectiveness and formulation of a $10 RU58841 gel from a Korean brand, questioning if ethanol is used to hold the active compounds. Concerns are raised about the feasibility of selling it at such a low price.
Kintor Pharma has started a Phase II trial in China for GT20029, a potential new treatment for hair loss. Participants are discussing the significance, potential release dates, and comparing it to other treatments and technologies like stem cell hair transplants and SAMIRNA.